1. Baekje Shenzhou's loss in the first half of the year expanded to 6.7 billion. Baekje Shenzhou announced its results for the first quarter of 2022. According to statistics, Baekje Shenzhou's revenue in the first half of 2022 was 4,265,438+billion yuan, down13.9% year-on-year; In the same period last year, the loss was 2.49 billion yuan, with a cumulative loss of 6.664 billion yuan.
Second, the reasons for the loss Baekje Shenzhou is a global and commercialized biotechnology company, mainly engaged in the research and development, production and commercialization of new drugs. Baekje Shenzhou Company is developing more than 40 kinds of products.
As for the reasons for the loss, Baekje Shenzhou explained that the reason for the increase in business loss was that the cooperative income decreased by 2.774 billion yuan, while the exchange rate rose by 77.65438 billion yuan. The decrease in cooperation income was mainly due to the cooperation advance payment of $650 million made by Novartis for Baize 'an in the first quarter of 20021.
In the fourth quarter of 2002/kloc-0, we provided a cooperation advance payment of USD 300 million for the TIGIT inhibitor osporimab.
Baekje Shenzhou has been losing money for nearly four years. According to statistics, the annual losses of 2018-202/kloc-0 were 4.74 billion yuan, 6.9.1billion yuan, 6.5438+0.38 billion yuan and 9.74 billion yuan respectively, totaling 33 billion yuan.
Some experts in the industry said that the innovative research and development cycle of drugs is long, it is difficult to recruit patients, the cost is high, the risk is high, and R&D and production are often needed? Burning money?
Third, although there are losses, what is there? Hematopoiety? Ability Although the company has been losing money, its product income has been increasing. Baekje Shenzhou achieved sales of 3.676 billion yuan in the first half of the year, compared with 65.438+58.3 billion yuan in the same period last year, up 654.38+0.32% year-on-year.
Baekje Shenzhou said that the company's revenue growth was mainly due to the increase in sales of zebutinib capsules and tillizumab injections independently developed by the company.